Search

Displaying results 2381 - 2390 of 10000 in total
  1. Drug

    ATP

    go.drugbank.com/drugs/DB00171
    InvestigationalNutraceutical

    An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.

  2. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).

  3. Drug

    Atidarsagene autotemcel

    go.drugbank.com/drugs/DB17538
    ApprovedInvestigational

    [L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic … [L45196] It was granted FDA approval under the brand name Lenmeldy in March 2024.[L50256]

    Categories: Complex MixturesSynonyms: Autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene
  4. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

    Categories: Drugs Used in Diabetes
  5. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS). … RPI-78M is being developed for the treatment of multiple sclerosis (MS).

  6. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]

  7. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug … [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.

    Categories: Immunoglobulin G
  8. Indication

    Influenza caused by pandemic (H1N1) 2009 virus

    go.drugbank.com/conditions/DBCOND0093734
    Drugs: Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)
    Synonyms: Influenza caused by pandemic (H1N1) 2009 virus
  9. Drug

    Oxyquinoline

    go.drugbank.com/drugs/DB11145
    ApprovedInvestigationalVet approved

    It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.

    Mixtures: INDIO (111-IN) OSSINA CURIUM NETHERLANDS, Trimo San
  10. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.